Vasculitis and IgA monoclonal gammopathy of cutaneous significance

Monoclonal gammopathy with cutaneous significance treated successfully with rituximab

“…The anti-CD20 antibody Rituximab is approved in combination with glucocorticoids for the treatment of patients with certain ANCA-associated vasculitis [6][7][8]. In the literature isolated case reports on the use of rituximab describe successful therapeutic outcomes in patients with cryoglobulinemic vasculitis [9] and vasculitis associated with monoclonal IgA in the meaning of MGCS [10]. Our cases support the observation that rituximab is also a treatment option for MGCS, but in off-label use.…”

Leukocytoclastic vasculitis associated with immunoglobulin A lambda monoclonal gammopathy of undetermined significance: A case report and review of previously reported cases

“…In one recalcitrant patient, rituximab therapy induced complete remission of vasculitis and resulted in the disappearance of IgA monoclonal gammopathy; it also enabled successful weaning from systemic steroids. 12 As this same treatment course induced four episodes of relapse in the current case, the use of molecular-targeted therapies, including rituximab, may prove effective.…”

“…15 Indeed, this subgroup of patients demonstrated monoclonal gammopathy with skin disease but without MM or lymphoproliferative disorders. Furthermore, Rousset et al 12 actually referred to their three cases of LCV associated with IgA monoclonal gammopathy as MGCS. The current case may also be appropriately classified as MGCS.…”

“…that included a rare case of overlapping IgA vasculitis and polyarteritis nodosa associated with IgA MM. Recently, Rousset et al . described three cases of LCV associated with IgA MGUS.…”

“… MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; N/D, not described. Reference did not describe which patient was cryoglobulin‐negative. …”